In a significant policy announcement, Trump stated that generic drugs imported into the U.S. will initially be exempt from tariffs for two years. However, starting in August 2028, a 100% tariff will be imposed, with the possibility of increasing to 200% in subsequent years. This move has sparked concerns and discussions regarding its impact on healthcare stocks and the pharmaceutical industry, with companies like AstraZeneca poised for changes under the new regulations.